


In the Claims

Amend the claims as follows:

1(Currently Amended) A compound of the structural formula I:



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:
wherein,

R represents hydrogen, or C₁-6 alkyl;

R₁ represents hydrogen or C₁-6 alkyl, CF₃, C₁-6 alkoxy, OH, COR^c, CO₂R₈,
CONHCH₂CO₂R, N(R)₂, said alkyl and alkoxy optionally substituted with 1-3 groups
selected from R^b;

X represents -(CHR₇)_p-;

Y represents -CO(CH₂)_n-, or -CH(OR)-;

Q represents N, CR_Y, or O, wherein R₂ is absent when Q is O;

R_Y represents H, or C₁-6 alkyl;

R_w represents H, C₁₋₆ alkyl, -C(O)C₁₋₆ alkyl, -C(O)OC₁₋₆ alkyl, -SO₂N(R)₂, -SO₂C₁₋₆ alkyl, -SO₂C₆₋₁₀ aryl, NO₂, CN or -C(O)N(R)₂;

R₂ represents hydrogen, C₁₋₁₀ alkyl, C₁₋₆ alkylSR, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -N(R)₂, -COOR, or -(CH₂)_nC₆₋₁₀ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R₃ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -(CH₂)_nCOOR, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nNHR₈, -(CH₂)_nN(R)₂, -(CH₂)_nN(R₈)₂, -(CH₂)_nNHCOOR, -(CH₂)_nN(R₈)CO₂R, -(CH₂)_nN(R₈)COR, -(CH₂)_nNHCOR, -(CH₂)_nCONH(R₈), aryl, -(CH₂)_nC₁₋₆-OR, CF₃, -(CH₂)_nSO₂R, -(CH₂)_nSO₂N(R)₂, -(CH₂)_nCON(R)₂, -(CH₂)_nCONHC(R)₃, -(CH₂)_nCONHC(R)₂CO₂R, -(CH₂)_nCOR₈, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups of R^a;

or, when Q is N, R₂ and R₃ taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

R₄ and R₅ independently represent hydrogen, C₁₋₆ alkoxy, OH, C₁₋₆ alkyl, COOR, SO₃H, C₁₋₆ alkylcarbonyl, S(O)_qRY, -O(CH₂)_nN(R)₂, -O(CH₂)_nCO₂R, -OPO(OH)₂, CF₃, -N(R)₂, nitro, cyano, C₁₋₆ alkylamino, or halogen;

R₆ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₆₋₁₀ aryl, -NH(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nC₅₋₁₀ heteroaryl, -NH(CH₂)_nC₅₋₁₀ heteroaryl, (C₆₋₁₀ aryl)O-, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₃₋₈ cycloalkyl, -COOR, -C(O)CO₂R, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from R^a;

R₇ represents hydrogen, C₁₋₆ alkyl, -(CH₂)_nCOOR or -(CH₂)_nN(R)₂,

R₈ represents -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_n C₃₋₁₀ heterocyclyl, C₁₋₆ alkoxy or -(CH₂)_nC₅₋₁₀ heteroaryl, -(CH₂)_nC₆₋₁₀ aryl said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R^a represents F, Cl, Br, I, CF₃, N(R)₂, NO₂, CN, -(CH₂)_nCOR₈, -(CH₂)_nCONHR₈, -(CH₂)_nCON(R₈)₂, -O(CH₂)_nCOOR, -NH(CH₂)_nOR, -COOR, -OCF₃, -NHCOR, -SO₂R, -SO₂NR₂, -SR, (C₁-C₆ alkyl)O-, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, (aryl)O-, -OH, (C₁-C₆ alkyl)S(O)_m-, H₂N-C(NH)-, (C₁-C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)NH-, -(C₁-C₆ alkyl)NR_w(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)O(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)S(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₁-C₆ alkyl)-C₃₋₁₀ heterocyclyl-R_w, -(CH₂)_n-Z¹-C(=Z²)N(R)₂, -(C₂₋₆ alkenyl)NR_w(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)O(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)S(CH₂)_nC₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)-C₃₋₁₀ heterocyclyl-R_w, -(C₂₋₆ alkenyl)-Z¹-C(=Z²)N(R)₂, -(CH₂)_nSO₂R, -(CH₂)_nSO₃H, -(CH₂)_nPO(OR)₂, cyclohexyl, morpholinyl, piperidyl, pyrrolidinyl, thiophenyl, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl, C₂₋₆ alkenyl, and C₁-C₁₀ alkyl, said alkyl, alkenyl, alkoxy, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, and isothiazolyl optionally substituted with 1-3 groups selected from C₁-C₆ alkyl, and COOR;

Z¹ and Z² independently represents NR_w, O, CH₂, or S;

R^b represents C₁₋₆ alkyl, -COOR, -SO₃R, -OPO(OH)₂, -(CH₂)_nC₆₋₁₀ aryl, or -(CH₂)_nC₅₋₁₀ heteroaryl;

R^c represents hydrogen, C₁₋₆ alkyl, or -(CH₂)_nC₆₋₁₀ aryl;

m is 0-3;

n is 0-3;

q is 0-2; and

p is 0-1,

provided that the compound of formula I is not 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-[5-(1-methylethyl)-2-thiaolyl]; 1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-3-pyridinyl ester; or 1H-Indole-3-acetamide, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-N-3-pyridinyl.

2(Original). A compound of the structural formula I wherein X is
CHR₇.

3 (Original). A compound according to claim 1 wherein Y is -
CO(CH₂)_n.

4(Original). A compound according to claim 1 wherein Y is CH(OR).

5(Original). A compound according to claim 1 wherein Q is N.

6(Original). A compound according to claim 1 wherein Q is CH.

7(Original). A compound according to claim 2 wherein R₆ is
(CH₂)_nC₆₋₁₀ aryl, (CH₂)_nC₅₋₁₀ heteroaryl, (CH₂)_nC₃₋₁₀ heterocyclyl, or (CH₂)_nC₃₋₈
cycloalkyl, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3
groups of R_a.

8(Original). A compound according to claim 6 wherein R₇ is hydrogen
or C₁₋₆ alkyl.

9(Original). A compound according to claim 6 wherein Q is N and n is
0.


10(Original). A compound according to claim 1 wherein Y is -
CO(CH₂)_n, Q is N, n is 0, R₂ is C₁₋₁₀ alkyl or C₁₋₆ alkylOH and R₃ is (CH₂)_nC₃₋₁₀
heterocyclyl, said heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R_a.

Cancel claims 11-24.

Add new claims 25 through 29:



25 (New). A composition comprising a pharmaceutically acceptable
carrier and an effective amount of a compound according to claim 1.

Table 1



The image displays a collection of chemical structures representing various substituents (R groups) for the polymer repeat unit. These structures are arranged in a grid-like fashion, separated by commas. The substituents include:


- A piperazine ring with a tert-butyl ester group (CO_2tBu) attached to one of the nitrogen atoms.
- A benzodioxole ring system with a methylene group (CH_2) attached to the nitrogen atom.
- A cyclohexyl group attached to a nitrogen atom.
- A polyether chain consisting of a nitrogen atom connected to a series of methylene groups ($n(\text{H}_2\text{C})$), which is then connected to a cyclohexyl group.
- A thiazole ring with a hydrogen atom (H) and a substituent X attached to the ring.
- A piperazine ring with a cyclohexyl group attached to one of the nitrogen atoms.
- A furan ring with a substituent X attached to the ring.
- A thiophene ring with a substituent Y and a substituent Z attached to the ring.
- A thiazole ring with a hydrogen atom (H) and a substituent X attached to the ring.
- A piperazine ring with a carbonyl group (C=O) attached to one of the nitrogen atoms, which is further connected to a cyclohexyl group.
- A piperazine ring with a carbonyl group (C=O) attached to one of the nitrogen atoms, which is further connected to a cyclohexyl group.
- A thiazole ring with a substituent X attached to the ring.
- A benzothiazole ring system with a substituent X attached to the ring.




n is 0 to 3; X, Y and Z, independently represent hydrogen or C₁₋₆ alkyl; and R_c represents hydrogen, halogen, C₁₋₆ alkyl, CF₃, OCF₃, N(CH₃)₃, COC₁₋₆ alkyl, or methoxy;

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

Table 3




wherein R represents:




n is 0 to 3; s is 1-5; X represents hydrogen or C₁₋₆ alkyl; and R^c represents hydrogen, halogen, C₁₋₆ alkyl, CF₃, OCF₃, N(CH₃)₂, COC₁₋₆ alkyl, or methoxy or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

29 (New). The compound according to claim 11 which is:

Table 4



or



wherein:

R^b and R^a independently represent hydrogen, methoxy, CO_2X , NHAc , or C_{1-6} alkyl;

R^d represents C_{1-6} alkyl, pyridinyl, -O-phenyl, phenyl, thienyl, said pyridinyl and phenyl optionally substituted with 1-3 halogen, CF_3 , OCF_3 , $\text{N}(\text{CH}_3)_2$, methoxy or C_{1-6} alkyl; and

R^e represents methoxy, $\text{O}(\text{CH}_2)_2\text{N}(\text{CH}_3)_2$, or OH ;

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.